---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-121726"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:22:35.450888+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Esperion enters RIPA amendment with $50M partial call, waiver of defaults

## Summary
- One-time partial call of $50M on Revenue Interests under amended Revenue Interest Purchase Agreement.
- Cumulative Purchaser Payments reduced to $177,777,778.
- Waived certain claimed defaults, breaches and Put Option Events related to new bank account.
- Other material terms of RIPA and Security Agreement remain unchanged.

## SEC filing metadata
- accession: 0001104659-22-121726
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465922121726/0001104659-22-121726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465922121726/tm2231228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-121726
- JSON: https://secwatch.observer/filing/0001104659-22-121726.json
- Plain text: https://secwatch.observer/filing/0001104659-22-121726.txt

## Key facts
- Material Agreements
  Esperion Therapeutics, Inc. amended Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement with the purchasers party thereto and Eiger III SA LLC valued at $50 million (effective 2022-11-23).
  - Action: amendment
  - Counterparty: the purchasers party thereto and Eiger III SA LLC
  - Value: $50 million
  - Effective: 2022-11-23
  source text: On November 23, 2022, Esperion Therapeutics, Inc. (the “Company”) entered into Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (the “RIPA Amendment”), by and among the Company, the purchasers party thereto (the “Purchasers”), and Eiger III SA LLC, as the collateral agent and administrative agent (the “Purchaser Agent”), which amends (i) the Revenue Interest Purchase Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465922121726/0001104659-22-121726-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.